Patents by Inventor Shizuo Kasai

Shizuo Kasai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BENZOATE COMPOUND
    Publication number: 20210403420
    Abstract: The present invention provides a benzoic acid ester compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. A compound represented by the formula (I) or a salt thereof has an enteropeptidase inhibitory effect and is useful as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like: [in the formula, each symbol is as defined in the specification].
    Type: Application
    Filed: August 26, 2019
    Publication date: December 30, 2021
    Inventors: Ryoma HARA, Kohei ASANO, Ayumu NIIDA, Shizuo KASAI, Tsuyoshi MAEKAWA
  • Aromatic compound
    Patent number: 11186565
    Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: November 30, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Seiji Miwatashi, Yasufumi Miyamoto, Koji Watanabe, Yayoi Nakayama, Yuko Hitomi, Jumpei Aida, Nobuyuki Takakura, Hideki Furukawa, Naoyoshi Noguchi, Yasuhiro Hirata, Kazuaki Takami, Norihito Tokunaga, Tomohiro Okawa, Akito Shibuya, Shizuo Kasai, Toshitake Kobayashi, Tsuyoshi Maekawa
  • Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders
    Patent number: 10968231
    Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: April 6, 2021
    Assignees: SCOHIA PHARMA, INC., TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Seiji Miwatashi, Yasufumi Miyamoto, Koji Watanabe, Yayoi Nakayama, Yuko Hitomi, Jumpei Aida, Nobuyuki Takakura, Hideki Furukawa, Naoyoshi Noguchi, Yasuhiro Hirata, Shizuo Kasai, Toshitake Kobayashi, Tsuyoshi Maekawa, Satoshi Sasaki, Shigemitsu Matsumoto
  • IP6K inhibitors
    Patent number: 10968178
    Abstract: The present invention aims to provide a heterocyclic compound having an IP6K inhibitory action and expected to be useful as a prophylactic or therapeutic agent for—diseases such as cardiac failure, diabetes and the like. A compound represented by the formula (I): wherein each symbol is as defined in the SPECIFICATION, or a salt thereof has an IP6K inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for diseases such as cardiac failure, diabetes and the like.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: April 6, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Yoshito Terao, Masashi Takahashi, Ryoma Hara, Kousuke Hidaka, Hideki Furukawa, Takeshi Yamasaki, Shizuo Kasai
  • Tetrahydronaphthyridine somatostatin receptor 5 antagonists
    Patent number: 9751878
    Abstract: A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein, or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent for the prophylaxis or treatment of diabetes mellitus are provided.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: September 5, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Hideki Hirose, Takeshi Yamasaki, Tohru Yamashita, Asato Kina, Yoichi Nishikawa
  • Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
    Patent number: 9605000
    Abstract: Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 28, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Masaki Ogino, Ryo Mizojiri, Takeshi Yamasaki, Hideki Hirose, Nobuyuki Takakura, Tohru Yamashita, Sachie Morimoto, Takashi Nakahata, Asato Kina
  • Aromatic ring compound
    Patent number: 9505772
    Abstract: The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: November 29, 2016
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shizuo Kasai, Hideyuki Igawa, Masashi Takahashi, Asato Kina
  • Heterocyclic compound
    Patent number: 9487509
    Abstract: The present invention relates to wherein each symbol is as defined in the specification. The compound of the present invention has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of disease and condition mediated by increased RBP4.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: November 8, 2016
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shizuo Kasai, Tomohiro Kaku, Masahiro Kamaura
  • Aromatic ring compound
    Patent number: 9440987
    Abstract: The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: September 13, 2016
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shizuo Kasai, Hideyuki Igawa, Masashi Takahashi, Asato Kina
  • HETEROCYCLIC COMPOUNDS
    Publication number: 20160237087
    Abstract: A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein, or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent for the prophylaxis or treatment of diabetes mellitus are provided.
    Type: Application
    Filed: April 27, 2016
    Publication date: August 18, 2016
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Hideki Hirose, Takeshi Yamasaki, Tohru Yamashita, Asato Kina, Yoichi Nishikawa
  • Benzimidazole derivatives as MCH receptor antagonists
    Patent number: 9365540
    Abstract: The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: June 14, 2016
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shizuo Kasai, Hideyuki Igawa, Masashi Takahashi, Tsuyoshi Maekawa, Keiko Kakegawa, Asato Kina, Jumpei Aida, Uttam Khamrai, Mrinalkanti Kundu
  • Tetrahydronaphthyridine somatostatin receptor 5 antagonists
    Patent number: 9353108
    Abstract: A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein, or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent for the prophylaxis or treatment of diabetes mellitus are provided.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: May 31, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Hideki Hirose, Takeshi Yamasaki, Tohru Yamashita, Asato Kina
  • HETEROCYCLIC COMPOUND
    Publication number: 20160060273
    Abstract: Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.
    Type: Application
    Filed: March 13, 2014
    Publication date: March 3, 2016
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo KASAI, Masaki OGINO, Ryo MIZOJIRI, Takeshi YAMASAKI, Hideki HIROSE, Nobuyuki TAKAKURA, Tohru YAMASHITA, Sachie MORIMOTO, Takashi NAKAHATA, Asato KINA
  • Heterocyclic compound
    Patent number: 9120777
    Abstract: A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein, or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent the prophylaxis or treatment of diabetes mellitus are provided.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: September 1, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Asato Kina, Hideki Hirose, Takeshi Yamasaki, Tohru Yamashita, Yoichi Nishikawa
  • HETEROCYCLIC COMPOUND
    Publication number: 20150119412
    Abstract: A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein, or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent the prophylaxis or treatment of diabetes mellitus are provided.
    Type: Application
    Filed: October 28, 2014
    Publication date: April 30, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Takashi Nakahata, Asato Kina, Hideki Hirose, Takeshi Yamasaki, Tohru Yamashita, Yoichi Nishikawa
  • AROMATIC RING COMPOUND
    Publication number: 20150111894
    Abstract: The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.
    Type: Application
    Filed: May 9, 2013
    Publication date: April 23, 2015
    Inventors: Shizuo Kasai, Hideyuki Igawa, Masashi Takahashi, Asato Kina
  • HETEROCYCLIC COMPOUND
    Publication number: 20150099777
    Abstract: A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein, or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent for the prophylaxis or treatment of diabetes mellitus are provided.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Hideki Hirose, Takeshi Yamasaki, Tohru Yamashita, Asato Kina, Yoichi Nishikawa
  • AROMATIC RING COMPOUND
    Publication number: 20150087672
    Abstract: The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.
    Type: Application
    Filed: May 9, 2013
    Publication date: March 26, 2015
    Inventors: Shizuo Kasai, Hideyuki Igawa, Masashi Takahashi, Asato Kina
  • BENZIMIDAZOLE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS
    Publication number: 20150018363
    Abstract: The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.
    Type: Application
    Filed: January 11, 2013
    Publication date: January 15, 2015
    Inventors: Shizuo Kasai, Hideyuki Igawa, Masashi Takahashi, Tsuyoshi Maekawa, Keiko Kakegawa, Tsuneo Yasuma, Asato Kina, Jumpei Aida, Uttam Khamrai, Mrinalkanti Kundu
  • Derivatives of N-acyl-N?-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes
    Patent number: 8853215
    Abstract: The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, which has a superior RBP4-lowering action and is useful as a pharmaceutical composition for the prophylaxis or treatment of a disease or condition mediated by an increase in RBP4.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: October 7, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Kevin Francis McGee, Jr.